Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, is proud to announce the appointment of Dr. Fred Grossman as President and Chief Medical Officer. Dr. Grossman joins the team with over two decades of experience in clinical development, having held executive posts at pharmaceutical giants such as Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Sunovion.
Along with his most recent post as President and Chief Medical Officer at Glenmark Pharmaceuticals and Chief Medical Officer at Mesoblast, Inc., Dr. Grossman brings his deep understanding of generics, complex generics, and next-generation biologics, including bi-specific antibodies, to the position. He will take up the mantle from Dr. Adrian Hepner this upcoming July 17th, 2023, and will lead Coya’s development programs, with the goal of advancing the treatment of Amyotrophic Lateral Sclerosis (ALS) through its lead asset, COYA 302.
We are immensely proud of Dr. Hepner for his diligent leadership and enduring excellence which have enabled Coya to reach its potential. We are delighted that Dr. Hepner will continue to contribute to the progress of the Company. Furthermore, we are excited to announce the joining of Dr. Grossman, who, with his extensive clinical experience and success in execution, will surely contribute to advancing Coya’s multi-modal Treg pipeline, offering innovative, safe and effective treatments to those with neurodegenerative and autoimmune disorders. Dr. Hepner is proud of the great achievements of Coya and is confident for its future prospects. Dr. Grossman remarked: “I am excited to build upon the success of Coya and to help it reach greater heights.”
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., based in Houston TX, is making a name for itself in the biotechnology sector. By creating a proprietary treatment focused on regulatory T cells (Tregs), they aim to reduce systemic inflammation and neuroinflammation, as well as address conditions like neurodegenerative, metabolic and autoimmune diseases.
Coya’s upcoming investigational product candidates bear multiple therapeutic modalities that can help to restore the anti-inflammatory and immunomodulatory functions of Tregs. Two of their main lead therapeutic programs are the cytokine biologic COYA 301 and the biologic combination COYA 302. Both are intended to have an effect on the expansion of Treg numbers, as well as depleting T effector functions and activated macrophages. In sum, Coya’s approach is to effectively suppress inflammation, by using two powerful mechanisms.
Our newest advancements in targeted therapeutics have the potential to offer incredible therapeutic benefits and economic value. We have created multiple clinical and preclinical development activities and ongoing and planned clinical trials to continue to push these boundaries. Our product candidates are currently showing a promising safety profile and are embarking on the journey of making their way onto the market, when we are able to secure the necessary regulatory approvals. With our advanced strategies, unique marketing processes, and extensive commercialization expertise, we are confident that our product candidates will be successful and provide us with solid returns. Keep tuned in to see how far these advancements will take us!